Journey Medical Co. (NASDAQ:DERM) CFO Joseph Benesch Sells 4,055 Shares

Journey Medical Co. (NASDAQ:DERM) CFO Joseph Benesch sold 4,055 shares of the company’s stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $5.40, for a total transaction of $21,897.00. Following the transaction, the chief financial officer now owns 56,655 shares of the company’s stock, valued at $305,937. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Journey Medical Stock Down 1.3 %

NASDAQ DERM opened at $5.33 on Friday. The firm has a market capitalization of $106.65 million, a P/E ratio of -17.19 and a beta of 0.93. Journey Medical Co. has a twelve month low of $1.60 and a twelve month high of $8.11. The firm has a fifty day moving average of $4.94. The company has a quick ratio of 0.94, a current ratio of 1.21 and a debt-to-equity ratio of 1.13.

Journey Medical (NASDAQ:DERM) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.27). The company had revenue of $13.03 million during the quarter, compared to analyst estimates of $14.91 million. Journey Medical had a negative net margin of 5.20% and a negative return on equity of 32.83%. Research analysts expect that Journey Medical Co. will post -0.95 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Roth Mkm started coverage on shares of Journey Medical in a report on Friday, June 28th. They set a “buy” rating and a $11.00 price target for the company. Roth Capital upgraded Journey Medical to a “strong-buy” rating in a report on Friday, June 28th.

Institutional Investors Weigh In On Journey Medical

Several large investors have recently modified their holdings of DERM. Nwam LLC bought a new position in Journey Medical in the 1st quarter worth approximately $41,000. Heron Bay Capital Management bought a new position in Journey Medical in the 1st quarter worth approximately $124,000. Rosalind Advisors Inc. bought a new position in Journey Medical in the 2nd quarter worth approximately $644,000. Finally, Acadian Asset Management LLC boosted its holdings in Journey Medical by 687.5% in the 1st quarter. Acadian Asset Management LLC now owns 222,663 shares of the company’s stock worth $817,000 after buying an additional 194,389 shares during the period. Hedge funds and other institutional investors own 7.25% of the company’s stock.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.